耐水脱硫石膏、粉煤灰胶结材的研究

本文较深入地研究了脱硫石膏粉煤灰化学成分、杂质、颗粒特征和激发剂等对脱硫石膏、粉煤灰胶结材性能的影响 研究表明 ,激发剂是影响脱硫石膏、粉煤灰胶结材性能的主要因素 这为脱硫石膏、粉煤灰资源化利用打下良好理论基础 经实际应用表明 ,研究结果与实际情况能很好相符     

正弦稳态扫频信号的产生与输出

介绍用计算机软件产生正弦稳态扫频信号的编程方法。通过对Ｄ／Ａ变换与Ａ／Ｄ采集的同步输出可以获得不同频率量程和设定电压的扫频输出     

一类高阶非线性系统的零解稳定性

由Барбащин公式得到的四阶常系数线性系统的Ляпунов函数出发，通过类比法构造了一类四阶非线性系统的Ляпунов函数，并由此得到了这些系统零解的全局渐近稳定性的充分条件     

Dissecting the genomic complexity underlying medulloblastoma

Medulloblastoma is an aggressively growing tumour, arising in the cerebellum or medulla/brain stem. It is the most common malignant brain tumour in children, and shows tremendous biological and clinical heterogeneity. Despite recent treatment advances, approximately 40% of children experience tumour recurrence, and 30% will die from their disease. Those who survive often have a significantly reduced quality of life. Four tumour subgroups with distinct clinical, biological and genetic profiles are currently identified. WNT tumours, showing activated wingless pathway signalling, carry a favourable prognosis under current treatment regimens. SHH tumours show hedgehog pathway activation, and have an intermediate prognosis. Group 3 and 4 tumours are molecularly less well characterized, and also present the greatest clinical challenges. The full repertoire of genetic events driving this distinction, however, remains unclear. Here we describe an integrative deep-sequencing analysis of 125 tumour-normal pairs, conducted as part of the International Cancer Genome Consortium (ICGC) PedBrain Tumor Project. Tetraploidy was identified as a frequent early event in Group 3 and 4 tumours, and a positive correlation between patient age and mutation rate was observed. Several recurrent mutations were identified, both in known medulloblastoma-related genes (CTNNB1, PTCH1, MLL2, SMARCA4) and in genes not previously linked to this tumour (DDX3X, CTDNEP1, KDM6A, TBR1), often in subgroup-specific patterns. RNA sequencing confirmed these alterations, and revealed the expression of what are, to our knowledge, the first medulloblastoma fusion genes identified. Chromatin modifiers were frequently altered across all subgroups. These findings enhance our understanding of the genomic complexity and heterogeneity underlying medulloblastoma, and provide several potential targets for new therapeutics, especially for Group 3 and 4 patients.